Category: basic life sciences retractions

E. coli gene paper falls to mistaken mutation

asmcoverResearchers in Germany have retracted their 2011 article in the Journal of Bacteriology after another lab pointed out a fatal error in the paper.

The article, “Escherichia coli Exports Cyclic AMP via TolC,” came from a group at Tübingen University led by Klaus Hantke. The paper focuses on the crucial role of the membrane channel TolC in exporting cyclic AMP (cAMP)-cAMP receptor protein (CRP) complex, which regulates nearly 200 E. coli genes. According to the abstract:

The data demonstrate that export of cAMP via TolC is a most efficient way of E. coli to lower high concentrations of cAMP in the cell and maintain its sensitivity in changing metabolic environments.

But the conclusions rested on a gene mutation that wasn’t quite what it seemed. Here’s the notice: Continue reading E. coli gene paper falls to mistaken mutation

Fifth retraction for Wayne State researcher who fudged figures

teresita
Teresita L. Briones

Another retraction has appeared for Teresita Briones, who used to study neuroscience at Wayne State University — the final of five papers flagged by the Office of Research Integrity for containing falsified data.

According to the ORI notice published in May, Briones “intentionally, knowingly, and recklessly engaged in research misconduct by falsifying and/or fabricating data.” This latest paper to be retracted, which looks at the role of specific receptor in chronic inflammation of nervous tissue in rats, has two figures that “were duplicated, reused and falsely relabelled, and claimed to represent different experiments,” according to the retraction note.

The retraction note for “Chronic neuroinflammation and cognitive impairment following transient global cerebral ischemia: role of fractalkine/CX3CR1 signaling,” published in the Journal of Neuroinflammation, specifies the problematic figures:

Continue reading Fifth retraction for Wayne State researcher who fudged figures

“The peer review process was compromised”: Inflammation drug paper pulled

12

A paper that screened for antibodies that target TNFα, a major source of inflammation, has been retraction after an investigation revealed the peer-review process may have been compromised.

We’ve seen the peer review process “compromised” in a handful of ways — from a mathematician who oversaw the process on several of his own papers, to some 250 papers subject to outright fake peer review. The note for this paper, published in Amino Acids, doesn’t go into details, so we can only wonder what happened in this particular case.

Here’s the note for “Structure‑based development and optimization of therapy antibody drugs against TNFα:”

Continue reading “The peer review process was compromised”: Inflammation drug paper pulled

Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Khachigian
Levon Khachigian

An investigation at the University of New South Wales in Australia has determined that a long-accused cancer researcher did not commit misconduct.

The investigation did find instances when Levon Khachigian breached the code of conduct, but Continue reading Cancer researcher cleared of misconduct, inquiry finds “genuine error or honest oversight”

Singapore investigation leads to two retractions, two more on the way

cov150hAuthors have retracted papers from Cell Metabolism and the Journal of Biological Chemistry after an investigation in Singapore found issues, including falsified data. The investigation is ongoing, and two additional retractions, along with two corrections, are on the horizon.

The investigation looked into papers by first authors Sudarsanareddy Lokireddy, now a postdoc at Harvard, and Sandhya Sriram, a postdoc at the Agency for Science, Technology and Research in Singapore. Led by the Nanyang Technological University in Singapore, where some of the work was done, the investigation concluded that there were issues with six papers on which either Sriram or Lokireddy was first author.

All authors but Lokireddy have agreed to retractions or corrections. Ravi Kambadur of NTU, and Mridula Sharma at the National University of Singapore, are the last two authors on all the papers.

According to a notice from the NTU, the “investigation found a number of instances of alterations to data” in three papers on which Lokireddy is first author. One of those was retracted December 1 by Cell Metabolism: Continue reading Singapore investigation leads to two retractions, two more on the way

Cancer research pioneer Robert Weinberg corrected Oncogene paper

onc_cimageRobert Weinberg, a prominent cancer researcher at the Whitehead Institute, issued a correction to a paper in Oncogene in May, fixing two errors missed during proofing.

We found this one a little late, obviously. It also appears to be a relatively minor correction, not one that appears worthy of retraction. We’ve gotten feedback from readers asking why we cover corrections; we chose to flag this one because Weinberg has had such an impact on his field — he discovered the first tumor-causing gene in humans, as well as the first tumor-suppressor gene — and his papers are often highly cited. He also has issued five retractions in the past, most of which for papers whose first author was a member of his lab, who is not a co-author on the Oncogene paper.

Here’s the correction note for “Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells:”

Continue reading Cancer research pioneer Robert Weinberg corrected Oncogene paper

Is an increase in retractions good news? Maybe, suggests new study

SEEIn Latin America, retractions for plagiarism and other issues have increased markedly — which may be a positive sign that editors and authors are paying closer attention to publishing ethics, according to a small study published in Science and Engineering Ethics.

The authors examined two major Latin American/Caribbean databases, which mostly include journals from Brazil, and have been indexing articles for more than 15 years. They found only 31 retractions, all of which appeared in 2008 or later. (Roughly half of the retractions were from journals indexed in the Thomas Reuters’  Journal of Citations Report®  (JCR).)

This was a notable result, the authors write: Continue reading Is an increase in retractions good news? Maybe, suggests new study

NSF investigating as more falsified results surface from mol bio researcher

Screen Shot 2015-12-04 at 5.22.53 PMAuthors of a paper on the origin and function of a family of transmembrane proteins have retracted it after an investigation at the University of Florida revealed that an author had falsified some results.

This is the third paper with falsifications that Chi Leung, a former UF postdoc, is responsible for; this summer, we reported on a retraction and a partial retraction of two other papers on which Leung was a co-author. The case is currently under investigation by the U.S. Office of Research Integrity National Science Foundation, a UF spokeswoman tells us.

The problems in the paper, “Phylogenetic, expression, and functional analyses of anoctamin homologs in Caenorhabditis elegans,” occur in a figure that compares mRNA levels in control and experimental populations of C. elegans. The paper was published in the American Journal of Physiology, and has been cited eight times, according to Thomson Scientific’s Web of Knowledge.

The retraction note explains that, according to the other authors, much of the data in the paper are valid:

Continue reading NSF investigating as more falsified results surface from mol bio researcher

Five years after a retraction, company’s stock is up more than 500%

wntloggawntresearchwebny1Is ethical behavior good for business?

Five years ago this month, Swedish pharmaceutical company WntResearch immediately notified shareholders when authors retracted a 2009 Proceedings of the National Academy of Sciences (PNAS) paper on a potential cancer therapy that was key to the company’s business.

At the time, the company’s decision to disclose the retraction hurt its finances, as WntResearch delayed its planned initial public offering for three weeks. It also offered investors and shareholders the opportunity to withdraw their shares of WntResearch stock.

But, aside from one of the paper’s co-authors, “No one did that,” Nils Brünner, WntResearch’s CEO, told us. Since the company’s IPO on December 17, 2010, its stock price has increased from Continue reading Five years after a retraction, company’s stock is up more than 500%

Cancer researcher contributed “false data” to 11 studies

ori-logoA former cancer researcher has falsified data in 11 studies, according to the results of a investigation scheduled to be published in the Federal Register tomorrow.

The Office of Research Integrity’s findings are based on an inquiry at Virginia Commonwealth University, where Girija Dasmahapatra worked until July of this year, investigating possible therapies for cancer. The misconduct affected research funded by three grants from the National Institutes of Health. Steven Grant, a researcher at VCU, is the principal investigator on the grants, each of which total over $2 million in funding. All of the 11 affected papers will be corrected or retracted, according to the ORI notice.

Two of the papers containing “falsified and/or fabricated” data — a study on an experimental combination of drugs for blood cancer and one on chemotherapies for rare forms of lymphoma  — were covered in press releases by VCU.

According to the notice in the Federal Register:

Continue reading Cancer researcher contributed “false data” to 11 studies